DuPont (NYSE: DD ) is scheduled to release its quarterly earnings report tomorrow, and with its stock at its highest levels in more than a decade, investors are pleased with the company's success lately. But some recent concerns about DuPont's earnings make this quarterly report crucial for the company's future prospects, and a disappointment could set the stage for a reversal in the stock's strong performance.
DuPont's gains have outpaced those of the Dow Jones Industrials (DJINDICES: ^DJI ) since the beginning of 2013, and over the long run, the favorable demographic trends that have encouraged greater agricultural activity have helped bolster its seed and fertilizer business. Yet the company is still sensitive to broader economic trends, and some parts of the world have seen a big slowdown that could hurt DuPont's earnings growth. Let's take an early look at what's been happening with DuPont over the past quarter and what we're likely to see in its quarterly report.
Hot Warren Buffett Companies For 2015: Konared Corp (KRED)
KonaRed Corporation., formerly TeamUpSport Inc., incorporated on October 4, 2010, is a development-stage company. The Company is focused to develop and commercialize on its Website www.teamupsport.com. As of May 31, 2011, the Company had not generated revenue. On October 4, 2013, the Company acquired Sandwich Isles Trading Co. Inc. dba KonaRed.
The Company's Website will be designed to integrate into a single online offering people�� interest in sports with the capabilities of online social networking. The Website will become a sports focused social networking Website.
Advisors' Opinion:- [By Bryan Murphy]
Two weeks ago, yours truly made the point that all beverage makers ranging from small niche players like National Beverage Corp. (NASDAQ:FIZZ) to the mega-sized names like The Coca-Cola Company (NYSE:KO) that little ol' KonaRed Corp. (OTCBB:KRED) was coming on fast... not just in terms of product innovation, but in terms of its retail footprint. Not that there was any doubt in the meantime, but KRED laid down another piece of evidence to that end today that should have the likes of KO and FIZZ concerned. Simply put, the flagship Konared product (juice from the fruit that surrounds coffee beans) is soon going to found on the shelves of 80 additional Canadian grocery stores.
- [By James E. Brumley]
Consider this an official warning for PepsiCo, Inc. (NYSE:PEP). And, The Coca-Cola Company (NYSE:KO) is being put on notice too. There's a newcomer in the world of functional beverages, and it's poised to be a disruptor for some of the beverage industry's presumably-prolific brands. This newcomer? KonaRed Corp. (OTCBB:KRED). It's not just a new name either. It's bringing a whole new flavor to the healthy drinks market that's not only creative, but delicious.
- [By Tabitha Jean Naylor]
Konared (OTCQB: KRED)
Konared’s mission is to reintroduce the world to coffee. Unlike many other start-ups that focus on providing yet another way to enjoy traditional coffee, which is made from toasted and pulverized coffee beans, Konared actually makes use of the coffee berry in order to produce its beverage.
- [By James E. Brumley]
If you're only a headline skimmer, it's a detail that would have been easy to overlook. For those who don't miss anything, however, they'll already know that beverage company Konared Corp. (OTCBB:KRED) is about to unveil a product that will put it toe-to-toe with the likes of The Coca-Cola Company (NYSE:KO) and PepsiCo, Inc. (NYSE:PEP). And, if history is any indication, while PepsiCo and Coca-Cola are apt to maintain their wider distribution, KonaRed is apt to beat them in enough places to carve out a nice piece of the market, and reward KRED shareholders in the process. Meanwhile, there's a good chance that most PEP and KO shareholders know - or even care - that the company they own a stake in is even competing in this arena. That arena? Coconut water.
Top 5 Healthcare Technology Companies To Invest In 2014: Strattec Security Corporation(STRT)
Strattec Security Corporation engages in the design, development, manufacture, and marketing of automotive access control products. The company?s products include mechanical locks and keys, electronically enhanced locks and keys, steering column and instrument panel ignition lock housings, latches, power sliding door systems, power lift gate systems, power deck lid systems, door handles, and related products. It also provides full service and aftermarket support for its products. The company offers its products primarily for automotive manufacturers. It markets its products in the United States, Canada, Mexico, Europe, South America, Korea, and China. The company was founded in 1994 and is headquartered in Milwaukee, Wisconsin.
Advisors' Opinion:- [By Monica Wolfe]
Strattec Security (STRT)
Last week Mario Gabelli increased his position in Strattec Security. The guru increased his position 4.82% by adding a total of 13,136 shares to his holdings. He bought these shares at an average price of $43.15, and since then the price per share has increased approximately 5%.
Top 5 Healthcare Technology Companies To Invest In 2014: Neuroderm Ltd (NDRM)
Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.
ND0612L for moderate Parkinson�� disease
ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.
The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.
The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.
ND0612H for severe Parkinson�� disease
The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.
ND0680 for severe Parkinson�� disease
ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680
ND0701 for severe Parkinson�� disease
ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.
ND0801 for Cognitive Disorders
ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.
The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.
Advisors' Opinion:- [By Johanna Bennett]
NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.
- [By Johanna Bennett]
NeuroDerm (NDRM) almost tripled in value to $18.14 during regular market hours after posting clinical trial results for its experimental treatment for Parkinson�� disease.
Top 5 Healthcare Technology Companies To Invest In 2014: Qlik Technologies Inc.(QLIK)
Qlik Technologies Inc. engages in the development, commercialization, and implementation of software products and related services for user-driven business intelligence that enables customers to make business decisions primarily in the Americas, Europe, the Asia-Pacific region, and Africa. It provides QlikView Business Discovery platform, which helps people create and share insights and analysis in groups and across organizations. Business users can explore data, ask and answer their own stream of questions, and follow their own path to insight on their own and in teams and groups. The company also offers maintenance and professional services. It sells its products to a range of industry verticals, including consumer packaged goods, financial services, pharmaceuticals, retail, manufacturing, technology, and healthcare through its direct sales force, as well as through an indirect channel partners comprising distribution partners, value-added resellers, system integrators, and original equipment manufacturers to license and support its software platform. The company was founded in 1993 and is headquartered in Radnor, Pennsylvania.
Advisors' Opinion:- [By Ant贸nio Costa]
Qlik Technologies Inc(NASDAQ: QLIK) Looks good as it breaks to new highs. Looking at the technical daily chart above, it shows very strong upward momentum as the stock is above all EMAs, with both 200-day and 50-day exp moving average going up. In addition, CMF and MACD also show very bullish signs.
- [By Garrett Cook]
Shares of Qlik Technologies (NASDAQ: QLIK) got a boost, shooting up 12.48 percent to $26.31 after the company reported better-than-expected quarterly results.
- [By Lauren Pollock]
Qlik Technologies Inc.'s(QLIK) third-quarter earnings soared due to a tax benefit, but higher costs more than offset revenue growth. Shares dropped as revenue missed expectations and the company’s outlook for the current quarter was short of analysts’ estimates.
No comments:
Post a Comment